Form 10-Q Calithera Biosciences, For: Sep 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Calithera Biosciences (CALA) Reports Q3 Loss of $0.49/Share
November 10, 2015 9:43 AM ESTCalithera Biosciences (NASDAQ: CALA) reported Q3 EPS of ($0.49), versus ($16.85) reported last year.
Anticipated Upcoming Milestones
Hematologic Phase 1 clinical trial data by year end 2015Initiation of six CB-839 combination expansion cohorts by year end 2015CB-839 combination therapy data in... MoreCalithera Biosciences (CALA) Files $150M Common Stock Shelf
November 10, 2015 9:41 AM ESTCalithera Biosciences (NASDAQ: CALA) filed a registration with the U.S. SEC to sell up to $150 million worth of common stock.
... More